Regulation of Immunity and Disease by the IL-1 Receptor Family Members IL-1R2 and IL-1R8

  • Martina Molgora
  • Domenico Supino
  • Cecilia GarlandaEmail author


Interleukin-1 and other IL-1 family members are key players in immunity and inflammation.

The activation of the IL-1 system is tightly regulated, through ligands with antagonistic or anti-inflammatory activity, or decoy and negative regulatory receptors. IL-1R2 and IL-1R8 (also known as SIGIRR) are members of the ILR family acting as negative regulators of the IL-1 system. IL-1R2 binds IL-1 and the accessory protein IL-1RAcP without activating signaling, thus modulating IL-1 availability for the signaling receptor. IL-1R8 dampens IL-1 receptor- and Toll Like Receptor-mediated cell activation and is a component of the receptor complex recognizing the anti-inflammatory cytokine IL-37.

The deregulated activation of the IL-1 system is the potential cause of detrimental local or systemic inflammatory reactions. Here, we summarize our current understanding of the function of IL-1R2 and IL-1R8, focusing on their role in pathological conditions, ranging from infectious and sterile inflammation, to cancer-related inflammation.


Interleukin-1 Inflammation Infection Inflammation-associated cancer 


Conflicts of Interest

The authors declare no conflicts of interest.


  1. 1.
    Dinarello CA (2010) Anti-inflammatory agents: present and future. Cell 140(6):935–950. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003–1018. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kang JY, Lee JO (2011) Structural biology of the Toll-like receptor family. Annu Rev Biochem 80:917–941. CrossRefPubMedGoogle Scholar
  4. 4.
    O’Neill LA (2006) How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 18(1):3–9. CrossRefPubMedGoogle Scholar
  5. 5.
    O’Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10–18. CrossRefPubMedGoogle Scholar
  6. 6.
    Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. CrossRefPubMedGoogle Scholar
  7. 7.
    Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 279(14):13677–13688CrossRefPubMedGoogle Scholar
  8. 8.
    Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20–38CrossRefPubMedGoogle Scholar
  9. 9.
    Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O’Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, Kelk P, van de Veerdonk F, Gabel C (2010) IL-1 family nomenclature. Nat Immunol 11(11):973. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67(3):1062–1071. CrossRefPubMedGoogle Scholar
  11. 11.
    Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10(2):103–110. CrossRefPubMedGoogle Scholar
  12. 12.
    Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720–3732. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Towne JE, Sims JE (2012) IL-36 in psoriasis. Curr Opin Pharmacol 12(4):486–490. CrossRefPubMedGoogle Scholar
  14. 14.
    Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633–652. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiiflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842. CrossRefPubMedGoogle Scholar
  17. 17.
    O’Neill LA, Sheedy FJ, McCoy CE (2011) MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11(3):163–175. CrossRefPubMedGoogle Scholar
  18. 18.
    Copeland NG, Silan CM, Kingsley DM, Jenkins NA, Cannizzaro LA, Croce CM, Huebner K, Sims JE (1991) Chromosomal location of murine and human IL-1 receptor genes. Genomics 9(1):44–50CrossRefPubMedGoogle Scholar
  19. 19.
    Morrison RN, Young ND, Nowak BF (2012) Description of an Atlantic salmon (Salmo salar L.) type II interleukin-1 receptor cDNA and analysis of interleukin-1 receptor expression in amoebic gill disease-affected fish. Fish Shellfish Immunol 32(6):1185–1190. CrossRefPubMedGoogle Scholar
  20. 20.
    Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261(5120):472–475CrossRefPubMedGoogle Scholar
  21. 21.
    McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, Brannan CI et al (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10(10):2821–2832PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Orlando S, Sironi M, Bianchi G, Drummond AH, Boraschi D, Yabes D, Mantovani A (1997) Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 272(50):31764–31769CrossRefPubMedGoogle Scholar
  23. 23.
    Lorenzen I, Lokau J, Dusterhoft S, Trad A, Garbers C, Scheller J, Rose-John S, Grotzinger J (2012) The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 586(8):1093–1100. CrossRefPubMedGoogle Scholar
  24. 24.
    Uchikawa S, Yoda M, Tohmonda T, Kanaji A, Matsumoto M, Toyama Y, Horiuchi K (2015) ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine 71(2):238–245. CrossRefPubMedGoogle Scholar
  25. 25.
    Martin P, Palmer G, Vigne S, Lamacchia C, Rodriguez E, Talabot-Ayer D, Rose-John S, Chalaris A, Gabay C (2013) Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leuk Biol 94(4):791–802. CrossRefGoogle Scholar
  26. 26.
    Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, Bird TA, Shanebeck K, Grabstein KH, Sims JE et al (1994) Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 153(12):5802–5809PubMedGoogle Scholar
  27. 27.
    Colotta F, Orlando S, Fadlon EJ, Sozzani S, Matteucci C, Mantovani A (1995) Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J Exp Med 181(6):2181–2186CrossRefPubMedGoogle Scholar
  28. 28.
    Orlando S, Matteucci C, Fadlon EJ, Buurman WA, Bardella MT, Colotta F, Introna M, Mantovani A (1997) TNF-alpha, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol 158(8):3861–3868PubMedGoogle Scholar
  29. 29.
    Liu C, Hart RP, Liu XJ, Clevenger W, Maki RA, De Souza EB (1996) Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 271(34):20965–20972CrossRefPubMedGoogle Scholar
  30. 30.
    Wang D, Zhang S, Li L, Liu X, Mei K, Wang X (2010) Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol 11(10):905–911. CrossRefPubMedGoogle Scholar
  31. 31.
    Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU (1998) The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 161(12):6871–6877PubMedGoogle Scholar
  32. 32.
    Malinowsky D, Lundkvist J, Laye S, Bartfai T (1998) Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 429(3):299–302CrossRefPubMedGoogle Scholar
  33. 33.
    Laye S, Lundkvist J, Bartfai T (1998) Human/mouse interleukin-1 receptor/receptor accessory protein interactions in IL-1beta-induced NFkappaB activation. FEBS Lett 429(3):307–311CrossRefPubMedGoogle Scholar
  34. 34.
    Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F, Mantovani A (1996) Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface “receptor” with anti-interleukin-1 function. J Exp Med 183(4):1841–1850CrossRefPubMedGoogle Scholar
  35. 35.
    Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18(1):87–96CrossRefPubMedGoogle Scholar
  36. 36.
    Kawaguchi Y, Nishimagi E, Tochimoto A, Kawamoto M, Katsumata Y, Soejima M, Kanno T, Kamatani N, Hara M (2006) Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci U S A 103(39):14501–14506. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 38(2):285–295. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, Introna M, Mantovani A (1996) Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol 156(7):2534–2541PubMedGoogle Scholar
  39. 39.
    Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177(10):7303–7311CrossRefPubMedGoogle Scholar
  40. 40.
    De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJ, Provasi E, Sarnicola ML, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego RA, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, Abrignani S, Pagani M (2016) Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45(5):1135–1147. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45(5):1122–1134. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Drevets DA, Schawang JE, Mandava VK, Dillon MJ, Leenen PJ (2010) Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features. J Immunol 185(4):2432–2441. CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hofkens W, Schelbergen R, Storm G, van den Berg WB, van Lent PL (2013) Liposomal targeting of prednisolone phosphate to synovial lining macrophages during experimental arthritis inhibits M1 activation but does not favor M2 differentiation. PLoS One 8(2):e54016. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A, Kundig TM (2011) Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci U S A 108(44):18055–18060. CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Pinteaux E, Parker LC, Rothwell NJ, Luheshi GN (2002) Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem 83(4):754–763CrossRefPubMedGoogle Scholar
  46. 46.
    McNamee EN, Ryan KM, Kilroy D, Connor TJ (2010) Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. Eur J Pharmacol 626(2–3):219–228. CrossRefPubMedGoogle Scholar
  47. 47.
    Trebec DP, Chandra D, Gramoun A, Li K, Heersche JN, Manolson MF (2007) Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem 101(1):205–220. CrossRefPubMedGoogle Scholar
  48. 48.
    Pou J, Martinez-Gonzalez J, Rebollo A, Rodriguez C, Rodriguez-Calvo R, Martin-Fuentes P, Cenarro A, Civeira F, Laguna JC, Alegret M (2011) Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim Biophys Acta 1811(9):556–563. CrossRefPubMedGoogle Scholar
  49. 49.
    Iwai H, Inaba M (2012) Fetal thymus graft prevents age-related hearing loss and up regulation of the IL-1 receptor type II gene in CD4(+) T cells. J Neuroimmunol 250(1–2):1–8. CrossRefPubMedGoogle Scholar
  50. 50.
    Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM (2009) Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 113(21):5125–5133. CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Spriggs MK, Nevens PJ, Grabstein K, Dower SK, Cosman D, Armitage RJ, McMahan CJ, Sims JE (1992) Molecular characterization of the interleukin-1 receptor (IL-1R) on monocytes and polymorphonuclear cells. Cytokine 4(2):90–95CrossRefPubMedGoogle Scholar
  52. 52.
    Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, Colotta F (1994) The type II “receptor” as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179(2):739–743CrossRefPubMedGoogle Scholar
  53. 53.
    Colotta F, Re F, Muzio M, Polentarutti N, Minty A, Caput D, Ferrara P, Mantovani A (1994) Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 269(17):12403–12406PubMedGoogle Scholar
  54. 54.
    Dickensheets HL, Donnelly RP (1997) IFN-gamma and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes. J Immunol 159(12):6226–6233PubMedGoogle Scholar
  55. 55.
    Kalliolias GD, Gordon RA, Ivashkiv LB (2010) Suppression of TNF-alpha and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol 185(11):7047–7056. CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Daun JM, Ball RW, Burger HR, Cannon JG (1999) Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 65(6):863–866CrossRefPubMedGoogle Scholar
  57. 57.
    Penton-Rol G, Orlando S, Polentarutti N, Bernasconi S, Muzio M, Introna M, Mantovani A (1999) Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol 162(5):2931–2938PubMedGoogle Scholar
  58. 58.
    Docagne F, Campbell SJ, Bristow AF, Poole S, Vigues S, Guaza C, Perry VH, Anthony DC (2005) Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci 21(5):1205–1214. CrossRefPubMedGoogle Scholar
  59. 59.
    Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR (2000) Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 275(51):40307–40315. CrossRefPubMedGoogle Scholar
  60. 60.
    Alcami A, Koszinowski UH (2000) Viral mechanisms of immune evasion. Immunol Today 21(9):447–455CrossRefPubMedGoogle Scholar
  61. 61.
    Giai C, Gonzalez CD, Sabbione F, Garofalo A, Ojeda D, Sordelli DO, Trevani AS, Gomez MI (2016) Staphylococcus aureus induces shedding of IL-1RII in monocytes and neutrophils. J Innate Immun 8(3):284–298. CrossRefPubMedGoogle Scholar
  62. 62.
    Khoufache K, Bondza PK, Harir N, Daris M, Leboeuf M, Mailloux J, Lemyre M, Foster W, Akoum A (2012) Soluble human IL-1 receptor type 2 inhibits ectopic endometrial tissue implantation and growth: identification of a novel potential target for endometriosis treatment. Am J Pathol 181(4):1197–1205. CrossRefPubMedGoogle Scholar
  63. 63.
    Simeoni E, Dudler J, Fleury S, Li J, Pagnotta M, Pascual M, von Segesser LK, Vassalli G (2007) Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg 31(2):222–228. CrossRefPubMedGoogle Scholar
  64. 64.
    Rauschmayr T, Groves RW, Kupper TS (1997) Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci U S A 94(11):5814–5819CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Chang H, Wang Y, Wu W, Li G, Hanawa H, Zou J (2013) Hydrodynamics-based delivery of an interleukin-1 receptor II fusion gene ameliorates rat autoimmune myocarditis by inhibiting IL-1 and Th17 cell polarization. Int J Mol Med 31(4):833–840. CrossRefPubMedGoogle Scholar
  66. 66.
    Bessis N, Guery L, Mantovani A, Vecchi A, Sims JE, Fradelizi D, Boissier MC (2000) The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol 30(3):867–875.<867::AID-IMMU867>3.0.CO;2-MCrossRefPubMedGoogle Scholar
  67. 67.
    Dawson J, Engelhardt P, Kastelic T, Cheneval D, MacKenzie A, Ramage P (1999) Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 38(5):401–406CrossRefGoogle Scholar
  68. 68.
    Martin P, Palmer G, Rodriguez E, Seemayer CA, Palomo J, Talabot-Ayer D, Gabay C (2017) Deficiency in IL-1 receptor type 2 aggravates K/BxN serum transfer-induced arthritis in mice but has no impact on systemic inflammatory responses. J Immunol 198(7):2916–2926. CrossRefPubMedGoogle Scholar
  69. 69.
    Lamacchia C, Palmer G, Bischoff L, Rodriguez E, Talabot-Ayer D, Gabay C (2010) Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice. J Immunol 185(4):2516–2524. CrossRefPubMedGoogle Scholar
  70. 70.
    Hirsch E, Irikura VM, Paul SM, Hirsh D (1996) Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 93(20):11008–11013CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Ritvo PG, Churlaud G, Quiniou V, Florez L, Brimaud F, Fourcade G, Mariotti-Ferrandiz E, Klatzmann D (2017) Tfr cells lack IL-2Ralpha but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells. Sci Immunol 2(15).
  72. 72.
    Kovach MA, Stringer KA, Bunting R, Wu X, San Mateo L, Newstead MW, Paine R, Standiford TJ (2015) Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res 16:29. CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F, Drulovic J (2009) The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 207(1–2):101–106. CrossRefPubMedGoogle Scholar
  74. 74.
    Garlind A, Brauner A, Hojeberg B, Basun H, Schultzberg M (1999) Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res 826(1):112–116CrossRefPubMedGoogle Scholar
  75. 75.
    Arend WP, Malyak M, Smith MF Jr, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK (1994) Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153(10):4766–4774PubMedGoogle Scholar
  76. 76.
    Jouvenne P, Vannier E, Dinarello CA, Miossec P (1998) Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 41(6):1083–1089.<1083::AID-ART15>3.0.CO;2-9CrossRefPubMedGoogle Scholar
  77. 77.
    van der Torren CR, Verrijn Stuart AA, Lee D, Meerding J, van de Velde U, Pipeleers D, Gillard P, Keymeulen B, de Jager W, Roep BO (2016) Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes. PLoS One 11(1):e0146649. CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Mora-Buch R, Dotti I, Planell N, Calderon-Gomez E, Jung P, Masamunt MC, Llach J, Ricart E, Batlle E, Panes J, Salas A (2015) Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunol.
  79. 79.
    Meusch U, Klingner M, Baerwald C, Rossol M, Wagner U (2013) Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther 15(6):R219. CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Kuznetsov NV, Zargari A, Gielen AW, von Stein OD, Musch E, Befrits R, Lofberg R, von Stein P (2014) Biomarkers can predict potential clinical responders to DIMS0150 a Toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol 14:79. CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, Benner R, Prens EP (1997) The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 158(6):2955–2963PubMedGoogle Scholar
  82. 82.
    Ruckert F, Dawelbait G, Winter C, Hartmann A, Denz A, Ammerpohl O, Schroeder M, Schackert HK, Sipos B, Kloppel G, Kalthoff H, Saeger HD, Pilarsky C, Grutzmann R (2010) Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One 5(8):e12243. CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M (2004) Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 100(7):1388–1396. CrossRefPubMedGoogle Scholar
  84. 84.
    Laios A, O’Toole SA, Flavin R, Martin C, Ring M, Gleeson N, D’Arcy T, McGuinness EP, Sheils O, Sheppard BL, O’ Leary JJ (2008) An integrative model for recurrence in ovarian cancer. Mol Cancer 7:8. CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Keita M, AinMelk Y, Pelmus M, Bessette P, Aris A (2011) Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: to a link between endometriosis and endometrioid ovarian cancer. J Obstet Gynaecol Res 37(2):99–107. CrossRefPubMedGoogle Scholar
  86. 86.
    Thomassen E, Renshaw BR, Sims JE (1999) Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11(6):389–399. CrossRefPubMedGoogle Scholar
  87. 87.
    Riva F, Polentarutti N, Tribbioli G, Mantovani A, Garlanda C, Turin L (2009) The expression pattern of TIR8 is conserved among vertebrates. Vet Immunol Immunopathol 131(1–2):44–49. CrossRefPubMedGoogle Scholar
  88. 88.
    Zhao J, Bulek K, Gulen MF, Zepp JA, Karagkounis G, Martin BN, Zhou H, Yu M, Liu X, Huang E, Fox PL, Kalady MF, Markowitz SD, Li X (2015) Human colon tumors express a dominant-negative form of SIGIRR that promotes inflammation and colitis-associated colon cancer in mice. Gastroenterology 149(7):1860–1871.e1868. CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Polentarutti N, Rol GP, Muzio M, Bosisio D, Camnasio M, Riva F, Zoja C, Benigni A, Tomasoni S, Vecchi A, Garlanda C, Mantovani A (2003) Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 14(4):211–218PubMedGoogle Scholar
  90. 90.
    Molgora M, Bonavita E, Ponzetta A, Riva F, Barbagallo M, Jaillon S, Popovic B, Bernardini G, Magrini E, Gianni F, Zelenay S, Jonjic S, Santoni A, Garlanda C, Mantovani A (2017) IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature 551(7678):110–114. CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Anselmo A, Riva F, Gentile S, Soldani C, Barbagallo M, Mazzon C, Feruglio F, Polentarutti N, Somma P, Carullo P, Angelini C, Bacci M, Mendolicchio GL, Voza A, Nebuloni M, Mantovani A, Garlanda C (2016) Expression and function of IL-1R8 (TIR8/SIGIRR): a regulatory member of the IL-1 receptor family in platelets. Cardiovasc Res 111(4):373–384. CrossRefPubMedGoogle Scholar
  92. 92.
    Veliz Rodriguez T, Moalli F, Polentarutti N, Paroni M, Bonavita E, Anselmo A, Nebuloni M, Mantero S, Jaillon S, Bragonzi A, Mantovani A, Riva F, Garlanda C (2012) Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection. Infect Immun 80(1):100–109. CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Gopal R, Birdsell D, Monroy FP (2008) Regulation of Toll-like receptors in intestinal epithelial cells by stress and Toxoplasma gondii infection. Parasite Immunol 30(11–12):563–576. CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Leemans JC, Butter LM, Teske GJ, Stroo I, Pulskens WP, Florquin S (2012) The Toll interleukin-1 receptor (IL-1R) 8/single Ig domain IL-1R-related molecule modulates the renal response to bacterial infection. Infect Immun 80(11):3812–3820. CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Nanthakumar N, Meng D, Goldstein AM, Zhu W, Lu L, Uauy R, Llanos A, Claud EC, Walker WA (2011) The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS One 6(3):e17776. CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E, Coe R, Kern M, Baechler EC, Behrens TW, Gregersen PK, Gulko PS (2005) Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 11(1–12):21–29. CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Ragnarsdottir B, Samuelsson M, Gustafsson MC, Leijonhufvud I, Karpman D, Svanborg C (2007) Reduced Toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 196(3):475–484. CrossRefPubMedGoogle Scholar
  98. 98.
    Kadota C, Ishihara S, Aziz MM, Rumi MA, Oshima N, Mishima Y, Moriyama I, Yuki T, Amano Y, Kinoshita Y (2010) Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol 162(2):348–361CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Khan MA, Steiner TS, Sham HP, Bergstrom KS, Huang JT, Assi K, Salh B, Tai IT, Li X, Vallance BA (2010) The single IgG IL-1-related receptor controls TLR responses in differentiated human intestinal epithelial cells. J Immunol 184(5):2305–2313. CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Li D, Zhang X, Chen B (2015) SIGIRR participates in negative regulation of LPS response and tolerance in human bladder epithelial cells. BMC Immunol 16:73. CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Ueno-Shuto K, Kato K, Tasaki Y, Sato M, Sato K, Uchida Y, Sakai H, Ono T, Suico MA, Mitsutake K, Tokutomi N, Kai H, Shuto T (2014) Lipopolysaccharide decreases single immunoglobulin interleukin-1 receptor-related molecule (SIGIRR) expression by suppressing specificity protein 1 (Sp1) via the Toll-like receptor 4 (TLR4)-p38 pathway in monocytes and neutrophils. J Biol Chem 289(26):18097–18109. CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Adib-Conquy M, Adrie C, Fitting C, Gattolliat O, Beyaert R, Cavaillon JM (2006) Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit Care Med 34(9):2377–2385. CrossRefPubMedGoogle Scholar
  103. 103.
    Costello DA, Carney DG, Lynch MA (2015) Alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR. Brain Behav Immun 46:70–79. CrossRefPubMedGoogle Scholar
  104. 104.
    Villena J, Suzuki R, Fujie H, Chiba E, Takahashi T, Tomosada Y, Shimazu T, Aso H, Ohwada S, Suda Y, Ikegami S, Itoh H, Alvarez S, Saito T, Kitazawa H (2012) Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inflammatory response via negative regulation in porcine antigen-presenting cells. Clin Vaccine Immunol 19(7):1038–1053. CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Davies JM, MacSharry J, Shanahan F (2010) Differential regulation of Toll-like receptor signalling in spleen and Peyer’s patch dendritic cells. Immunology 131(3):438–448. CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Vilia MG, Fonte E, Veliz Rodriguez T, Tocchetti M, Ranghetti P, Scarfo L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Ghia P, Muzio M (2017) The inhibitory receptor Toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. Leuk Lymphoma 58(10):2419–2425. CrossRefPubMedGoogle Scholar
  107. 107.
    Campesato LF, Silva APM, Cordeiro L, Correa BR, Navarro FCP, Zanin RF, Marcola M, Inoue LT, Duarte ML, Molgora M, Pasqualini F, Massara M, Galante P, Barroso-Sousa R, Polentarutti N, Riva F, Costa ET, Mantovani A, Garlanda C, Camargo AA (2017) High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. Oncotarget 8(30):49470–49483. CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Vilia MG, Tocchetti M, Fonte E, Sana I, Muzio M (2017) Characterization of a long isoform of IL-1R8 (TIR8/SIGIRR). Eur Cytokine Netw 28(2):63–69. CrossRefPubMedGoogle Scholar
  109. 109.
    Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X (2003) SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 4(9):920–927. CrossRefPubMedGoogle Scholar
  110. 110.
    Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, Muzio M, Bergottini R, Scanziani E, Vecchi A, Hirsch E, Mantovani A (2004) Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A 101(10):3522–3526. CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Qin J, Qian Y, Yao J, Grace C, Li X (2005) SIGIRR inhibits interleukin-1 receptor- and Toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 280(26):25233–25241. CrossRefPubMedGoogle Scholar
  112. 112.
    Lech M, Garlanda C, Mantovani A, Kirschning CJ, Schlondorff D, Anders HJ (2007) Different roles of TiR8/Sigirr on Toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells. Kidney Int 72(2):182–192. CrossRefPubMedGoogle Scholar
  113. 113.
    Bulek K, Swaidani S, Qin J, Lu Y, Gulen MF, Herjan T, Min B, Kastelein RA, Aronica M, Kosz-Vnenchak M, Li X (2009) The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol 182(5):2601–2609. CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Tomasoni R, Morini R, Lopez-Atalaya JP, Corradini I, Canzi A, Rasile M, Mantovani C, Pozzi D, Garlanda C, Mantovani A, Menna E, Barco A, Matteoli M (2017) Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects. Elife 6.
  115. 115.
    Li X, Qin J (2005) Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med (Berl) 83(4):258–266. CrossRefGoogle Scholar
  116. 116.
    Gong J, Wei T, Stark RW, Jamitzky F, Heckl WM, Anders HJ, Lech M, Rossle SC (2010) Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach. J Struct Biol 169(3):323–330. CrossRefPubMedGoogle Scholar
  117. 117.
    Guven-Maiorov E, Keskin O, Gursoy A, Nussinov R (2015) A structural view of negative regulation of the Toll-like receptor-mediated inflammatory pathway. Biophys J 109(6):1214–1226. CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Garlanda C, Anders HJ, Mantovani A (2009) TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30(9):439–446. CrossRefPubMedGoogle Scholar
  119. 119.
    Drexler SK, Kong P, Inglis J, Williams RO, Garlanda C, Mantovani A, Yazdi AS, Brennan F, Feldmann M, Foxwell BM (2010) SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum 62(8):2249–2261. CrossRefPubMedGoogle Scholar
  120. 120.
    Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X (2010) The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32(1):54–66. CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Xiao H, Yin W, Khan MA, Gulen MF, Zhou H, Sham HP, Jacobson K, Vallance BA, Li X (2010) Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 139(2):574–585. CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Patterson NJ, Werling D (2013) To con protection: TIR-domain containing proteins (Tcp) and innate immune evasion. Vet Immunol Immunopathol 155(3):147–154. CrossRefPubMedGoogle Scholar
  123. 123.
    Newman RM, Salunkhe P, Godzik A, Reed JC (2006) Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect Immun 74(1):594–601. CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Low LY, Mukasa T, Reed JC, Pascual J (2007) Characterization of a TIR-like protein from Paracoccus denitrificans. Biochem Biophys Res Commun 356(2):481–486. CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Imbert PR, Louche A, Luizet JB, Grandjean T, Bigot S, Wood TE, Gagne S, Blanco A, Wunderley L, Terradot L, Woodman P, Garvis S, Filloux A, Guery B, Salcedo SP (2017) A Pseudomonas aeruginosa TIR effector mediates immune evasion by targeting UBAP1 and TLR adaptors. EMBO J 36(13):1869–1887. CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11(11):1014–1022. CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF (2015) IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 16(4):354–365. CrossRefPubMedGoogle Scholar
  128. 128.
    Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, Kim S, Dinarello CA (2015) Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A 112(8):2497–2502. CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, Puccetti M, Garlanda C, Kim S, Li S, van de Veerdonk FL, Dinarello CA, Romani L (2014) IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog 10(11):e1004462. CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Lunding L, Webering S, Vock C, Schroder A, Raedler D, Schaub B, Fehrenbach H, Wegmann M (2015) IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy 70(4):366–373. CrossRefPubMedGoogle Scholar
  131. 131.
    Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Muller M, Kersten S, Li S, Kim S, Eini H, Lewis EC, Joosten LA, Tilg H, Netea MG, Tack CJ, Dinarello CA, Stienstra R (2014) IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun 5:4711. CrossRefPubMedGoogle Scholar
  132. 132.
    Cavalli G, Justice JN, Boyle KE, D’Alessandro A, Eisenmesser EZ, Herrera JJ, Hansen KC, Nemkov T, Stienstra R, Garlanda C, Mantovani A, Seals DR, Dagna L, Joosten LA, Ballak DB, Dinarello CA (2017) Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A 114(9):2313–2318. CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46–56. CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Bozza S, Zelante T, Moretti S, Bonifazi P, DeLuca A, D’Angelo C, Giovannini G, Garlanda C, Boon L, Bistoni F, Puccetti P, Mantovani A, Romani L (2008) Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 180(6):4022–4031CrossRefPubMedGoogle Scholar
  135. 135.
    Garlanda C, Di Liberto D, Vecchi A, La Manna MP, Buracchi C, Caccamo N, Salerno A, Dieli F, Mantovani A (2007) Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol 179(5):3119–3125CrossRefPubMedGoogle Scholar
  136. 136.
    Huang X, Hazlett LD, Du W, Barrett RP (2006) SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling. J Immunol 177(1):548–556CrossRefPubMedGoogle Scholar
  137. 137.
    Horne DJ, Randhawa AK, Chau TT, Bang ND, Yen NT, Farrar JJ, Dunstan SJ, Hawn TR (2012) Common polymorphisms in the PKP3-SIGIRR-TMEM16J gene region are associated with susceptibility to tuberculosis. J Infect Dis 205(4):586–594. CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Blok DC, van Lieshout MH, Hoogendijk AJ, Florquin S, de Boer OJ, Garlanda C, Mantovani A, van’t Veer C, de Vos AF, van der Poll T (2014) Single immunoglobulin interleukin-1 receptor-related molecule impairs host defense during pneumonia and sepsis caused by Streptococcus pneumoniae. J Innate Immun 6(4):542–552. CrossRefPubMedGoogle Scholar
  139. 139.
    Sham HP, Yu EY, Gulen MF, Bhinder G, Stahl M, Chan JM, Brewster L, Morampudi V, Gibson DL, Hughes MR, McNagny KM, Li X, Vallance BA (2013) SIGIRR, a negative regulator of TLR/IL-1R signalling promotes microbiota dependent resistance to colonization by enteric bacterial pathogens. PLoS Pathog 9(8):e1003539. CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Drexler SK, Foxwell BM (2010) The role of Toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 42(4):506–518. CrossRefPubMedGoogle Scholar
  141. 141.
    Russell SE, Stefanska AM, Kubica M, Horan RM, Mantovani A, Garlanda C, Fallon PG, Walsh PT (2013) Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by gammadelta T cells. J Immunol 191(6):3337–3346. CrossRefPubMedGoogle Scholar
  142. 142.
    Lech M, Skuginna V, Kulkarni OP, Gong J, Wei T, Stark RW, Garlanda C, Mantovani A, Anders HJ (2010) Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 220(5):596–607. CrossRefPubMedGoogle Scholar
  143. 143.
    Wang DY, Su C, Chen GM, Pan HF, Wang FM, Liu GL, Hao L, Wang DG, Ye DQ (2015) The decreased frequency of SIGIRR-positive CD4+ T cells in peripheral blood of patients with SLE and its correlation with disease activity. Mol Biol Rep 42(2):423–430. CrossRefPubMedGoogle Scholar
  144. 144.
    Sanchez E, Garcia-Bermudez M, Jimenez-Alonso J, de Ramon E, Sanchez-Roman J, Ortego-Centeno N, Witte T, D'Alfonso S, Pons-Estel B, Anders HJ, Alarcon-Riquelme ME, Martin J (2012) Association study of IRAK-M and SIGIRR genes with SLE in a large European-descent population. Lupus 21(11):1166–1171. CrossRefPubMedGoogle Scholar
  145. 145.
    Zhu Y, Wang DG, Yang XK, Tao SS, Huang Q, Pan HF, Feng CC, Ye DQ (2014) Emerging role of SIGIRR rs7396562(T/G) polymorphism in systemic lupus erythematosus in a Chinese population. Inflammation 37(5):1847–1851. CrossRefPubMedGoogle Scholar
  146. 146.
    Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ (2008) Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 205(8):1879–1888. CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Nakashima K, Hirota T, Obara K, Shimizu M, Jodo A, Kameda M, Doi S, Fujita K, Shirakawa T, Enomoto T, Kishi F, Yoshihara S, Matsumoto K, Saito H, Suzuki Y, Nakamura Y, Tamari M (2006) An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway. J Hum Genet 51(4):284–291. CrossRefPubMedGoogle Scholar
  148. 148.
    Lech M, Avila-Ferrufino A, Allam R, Segerer S, Khandoga A, Krombach F, Garlanda C, Mantovani A, Anders HJ (2009) Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol 183(6):4109–4118. CrossRefPubMedGoogle Scholar
  149. 149.
    Noris M, Cassis P, Azzollini N, Cavinato R, Cugini D, Casiraghi F, Aiello S, Solini S, Cassis L, Mister M, Todeschini M, Abbate M, Benigni A, Trionfini P, Tomasoni S, Mele C, Garlanda C, Polentarutti N, Mantovani A, Remuzzi G (2009) The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. J Immunol 183(7):4249–4260. CrossRefPubMedGoogle Scholar
  150. 150.
    Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, Armstrong ME, Garlanda C, Mantovani A, O'Neill LA, Mills KH, Lynch MA (2008) IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem 105(5):1960–1969. CrossRefPubMedGoogle Scholar
  151. 151.
    Andre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ (2005) Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem 95(2):324–330. CrossRefPubMedGoogle Scholar
  152. 152.
    Watson MB, Costello DA, Carney DG, McQuillan K, Lynch MA (2010) SIGIRR modulates the inflammatory response in the brain. Brain Behav Immun 24(6):985–995. CrossRefPubMedGoogle Scholar
  153. 153.
    Costello DA, Watson MB, Cowley TR, Murphy N, Murphy Royal C, Garlanda C, Lynch MA (2011) Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice. J Neurosci 31(10):3871–3879. CrossRefPubMedGoogle Scholar
  154. 154.
    Na ES, Nelson ED, Kavalali ET, Monteggia LM (2013) The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. Neuropsychopharmacology 38(1):212–219. CrossRefPubMedGoogle Scholar
  155. 155.
    Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581–592. CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
    Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, Altuntas CZ, Wald D, Ma C, Zhou H, Tuohy VK, Fairchild RL, de la Motte C, Cua D, Vallance BA, Li X (2007) The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26(4):461–475. CrossRefPubMedGoogle Scholar
  157. 157.
    Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, Sironi M, Nebuloni M, Zorini EO, Scanziani E, Mantovani A (2007) Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 67(13):6017–6021. CrossRefPubMedGoogle Scholar
  158. 158.
    Yamada Y, Hata K, Hirose Y, Hara A, Sugie S, Kuno T, Yoshimi N, Tanaka T, Mori H (2002) Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 62(22):6367–6370PubMedGoogle Scholar
  159. 159.
    Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F (2009) The role of Toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma 50(10):1573–1580. CrossRefPubMedGoogle Scholar
  160. 160.
    Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F (2009) Expression and function of Toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 144(4):507–516. CrossRefPubMedGoogle Scholar
  161. 161.
    Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B, Mantovani A, Ponzoni M, Ghia P, Garlanda C, Caligaris-Cappio F, Muzio M (2011) Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood 118(3):660–669. CrossRefPubMedGoogle Scholar
  162. 162.
    Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, Anagnostopoulos A, Lamnissou K, Caligaris-Cappio F, Stamatopoulos K, Ghia P, Muzio M, Belessi C (2011) Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96(11):1644–1652. CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 99(10):6955–6960. CrossRefPubMedPubMedCentralGoogle Scholar
  164. 164.
    Brown GT, Narayanan P, Li W, Silverstein RL, McIntyre TM (2013) Lipopolysaccharide stimulates platelets through an IL-1beta autocrine loop. J Immunol 191(10):5196–5203. CrossRefPubMedGoogle Scholar
  165. 165.
    Beaulieu LM, Freedman JE (2010) The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res 125(3):205–209. CrossRefPubMedGoogle Scholar
  166. 166.
    Levi M, Lowenberg EC (2008) Thrombocytopenia in critically ill patients. Semin Thromb Hemost 34(5):417–424. CrossRefPubMedGoogle Scholar
  167. 167.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. CrossRefPubMedGoogle Scholar
  168. 168.
    Chaix J, Tessmer MS, Hoebe K, Fuseri N, Ryffel B, Dalod M, Alexopoulou L, Beutler B, Brossay L, Vivier E, Walzer T (2008) Cutting edge: priming of NK cells by IL-18. J Immunol 181(3):1627–1631CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton V, Colpitts SL, Beauchemin N, Saleh M (2015) The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43(4):751–763. CrossRefPubMedGoogle Scholar
  170. 170.
    Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17(9):1025–1036. CrossRefPubMedGoogle Scholar
  171. 171.
    Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16(1):7–19. CrossRefPubMedGoogle Scholar
  172. 172.
    Stojanovic A, Cerwenka A (2011) Natural killer cells and solid tumors. J Innate Immun 3(4):355–364. CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Martina Molgora
    • 1
  • Domenico Supino
    • 1
  • Cecilia Garlanda
    • 1
    • 2
    Email author
  1. 1.Department of Inflammation and ImmunologyHumanitas Clinical and Research CenterRozzanoItaly
  2. 2.Department of Biomedical SciencesHumanitas UniversityPieve EmanueleItaly

Personalised recommendations